BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990;98:1013-6. [PMID: 2179027 DOI: 10.1016/0016-5085(90)90027-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol 2007;46:365-71. [PMID: 17223219 DOI: 10.1016/j.jhep.2006.12.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
2 Webb GJ, Rahman SR, Levy C, Hirschfield GM. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther 2018;47:1213-9. [PMID: 29468705 DOI: 10.1111/apt.14579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
3 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
5 Khandelwal M, Malet PF. Pruritus associated with cholestasis. A review of pathogenesis and management. Dig Dis Sci 1994;39:1-8. [PMID: 8281842 DOI: 10.1007/BF02090052] [Cited by in Crossref: 36] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Kriegermeier A, Green R. Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies. Front Med (Lausanne) 2020;7:149. [PMID: 32432119 DOI: 10.3389/fmed.2020.00149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Jagadisan B, Srivastava A. Child with Jaundice and Pruritus: How to Evaluate? Indian J Pediatr 2016;83:1311-20. [PMID: 26932879 DOI: 10.1007/s12098-016-2058-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
8 Jimenez F, Monte MJ, El-Mir MY, Pascual MJ, Marin JJ. Chronic renal failure-induced changes in serum and urine bile acid profiles. Dig Dis Sci 2002;47:2398-406. [PMID: 12452369 DOI: 10.1023/a:1020575001944] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
9 Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Child 1993;69:141-3. [PMID: 8024298 DOI: 10.1136/adc.69.1.141] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
10 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
11 Ekinci S, Karnak I, Gürakan F, Yüce A, Senocak ME, Cahit Tanyel F, Büyükpamukçu N. Partial external biliary diversion for the treatment of intractable pruritus in children with progressive familial intrahepatic cholestasis: report of two cases. Surg Today. 2008;38:726-730. [PMID: 18668316 DOI: 10.1007/s00595-007-3736-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
12 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 2012;130:147-158. [PMID: 21801835 DOI: 10.1016/j.jsbmb.2011.06.012] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 7.6] [Reference Citation Analysis]
14 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]